ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - אבקה להכנת תרחיף - amoxicillin as trihydrate 50 mg/ml; clavulanic acid as potassium salt 12.5 mg/ml - ampicillin and enzyme inhibitor - ampicillin and enzyme inhibitor - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused by beta-lactamase producing organisms which are susceptible to augmentin and are resistant to other beta-lactam antibiotics.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate 125 mg / 5 ml; clavulanic acid as potassium 31.25 mg / 5 ml - suspension - ampicillin and enzyme inhibitor - fot the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused also by beta-lactamase producing organisms which are susceptible to augmentin and are resistant to other beta-lactam antibiotics.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - טבליות מצופות פילם - amoxicillin as trihydrate 875 mg; clavulanic acid as potassium salt 125 mg - ampicillin and enzyme inhibitor - ampicillin and enzyme inhibitor - short-term treatment of bacterial infections at the following sites: upper/lower respiratory tract infections, genito-urinary tract infections, skin and soft tissue infections, bone and joint infections, dental infections and other infections.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - ampicillin as sodium 500 mg; sulbactam as sodium 250 mg - powder for solution for injection - ampicillin and enzyme inhibitor - sulbactam sodium/ampicillin sodium im/iv is indicated for the treatment of infections due to susceptible beta-lactamase producing strains of microorganisms in the following conditions: 1) skin and skin structure infections. 2) intra-abdominal infections. 3) gynecological infections.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ampicillin as sodium; sulbactam as sodium - אבקה להכנת תמיסה לזריקה - ampicillin as sodium 1000 mg; sulbactam as sodium 500 mg - ampicillin and enzyme inhibitor - ampicillin and enzyme inhibitor - sulbactam sodium/ampicillin sodium im/iv is indicated for the treatment of infections due to susceptible beta-lactamase producing strains of microorganisms in the following conditions: 1) skin and skin structure infections. 2) intra-abdominal infections. 3) gynecological infections.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ampicillin as sodium; sulbactam as sodium - אבקה להכנת תמיסה לזריקה - ampicillin as sodium 2000 mg; sulbactam as sodium 1000 mg - ampicillin and enzyme inhibitor - ampicillin and enzyme inhibitor - sulbactam sodium/ampicillin sodium im/iv is indicated for the treatment of infections due to susceptible beta-lactamase producing strains of microorganisms in the following conditions: 1) skin and skin structure infections. 2) intra-abdominal infections. 3) gynecological infections.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - טבליות מצופות פילם - amoxicillin as trihydrate 250 mg; clavulanic acid as potassium salt 125 mg - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused also by beta-lactamase producing organisms witch are susceptible to augmentin and are resistant to other beta-lactam antibiotics.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - טבליות מצופות פילם - amoxicillin as trihydrate 500 mg; clavulanic acid as potassium salt 125 mg - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused by beta-lactamase producing organisms which are susceptible to augmentin and are resistant to other beta-lactam antibiotics.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin as disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.